| MAP2K1-mutated melanocytic tumors have reproducible histopathologic features and share similarities with melanocytic tumors with BRAF V600E mutations. | MAP2K1-mutated melanocytic tumors have reproducible histopathologic features and share similarities with melanocytic tumors with BRAF V600E mutations.
Alomari AK, Harms PW, Andea AA, Warren SJ. | 03/21/2024 |
| Activating mutations drive human MEK1 kinase using a gear-shifting mechanism. | Activating mutations drive human MEK1 kinase using a gear-shifting mechanism.
Patil K, Wang Y, Chen Z, Suresh K, Radhakrishnan R., Free PMC Article | 11/3/2023 |
| Modeling Osteoarthritis: MiR-16-5p Attenuates IL-1beta Induced Chondrocyte Dysfunction by Targeting MAP2K1 through the MAPK Pathway. | Modeling Osteoarthritis: MiR-16-5p Attenuates IL-1β Induced Chondrocyte Dysfunction by Targeting MAP2K1 through the MAPK Pathway.
Xu P, Zhang X, Li Q. | 10/28/2023 |
| Evolutionary history of MEK1 illuminates the nature of deleterious mutations. | Evolutionary history of MEK1 illuminates the nature of deleterious mutations.
Andrianova EP, Marmion RA, Shvartsman SY, Zhulin IB., Free PMC Article | 08/30/2023 |
| Clinical associations of BRAF and MAP2K1 mutations in pediatric Langerhans cell histiocytosis: When 1 + 1 = 3. | Clinical associations of BRAF and MAP2K1 mutations in pediatric Langerhans cell histiocytosis: When 1 + 1 = 3.
Kemps PG, van den Bos C, van Halteren AGS, International Study Group. | 08/4/2023 |
| Genetic variants of SOS2, MAP2K1 and RASGRF2 in the RAS pathway genes predict survival of HBV-related hepatocellular carcinoma patients. | Genetic variants of SOS2, MAP2K1 and RASGRF2 in the RAS pathway genes predict survival of HBV-related hepatocellular carcinoma patients.
Lin Q, Qiu M, Wei X, Xiang Z, Zhou Z, Ji I, Liang X, Zhou X, Wen Q, Liu Y, Yu H. | 05/30/2023 |
| Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer. | Response to MEK Inhibitor Therapy in MAP2K1 (MEK1) K57N Non-Small-Cell Lung Cancer and Genomic Landscape of MAP2K1 Mutations in Non-Small-Cell Lung Cancer.
Cheng ML, Lee JK, Kumar R, Klein H, Raskina K, Schrock AB, Michael KS, Mazor T, Cerami E, Oxnard GR, Liu D, Beltran H, Sholl LM, Nishino M, Jänne PA. | 03/8/2023 |
| High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer. | High-Throughput Functional Evaluation of MAP2K1 Variants in Cancer.
Mizuno S, Ikegami M, Koyama T, Sunami K, Ogata D, Kage H, Yanagaki M, Ikeuchi H, Ueno T, Tanikawa M, Oda K, Osuga Y, Mano H, Kohsaka S., Free PMC Article | 02/4/2023 |
| Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children. | Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children.
Yang Y, Wang C, Wang D, Cui L, Li N, Lian H, Ma H, Zhao Y, Zhang L, Liu W, Wang Y, Wu W, Zhang R, Li Z, Wang T. | 08/13/2022 |
| Structure of mitogen-activated protein kinase kinase 1 in the DFG-out conformation. | Structure of mitogen-activated protein kinase kinase 1 in the DFG-out conformation.
Nakae S, Kitamura M, Fujiwara D, Sawa M, Shirai T, Fujii I, Tada T., Free PMC Article | 04/16/2022 |
| The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma. | The Predictive Value of MAP2K1/2 Mutations on Efficiency of Immunotherapy in Melanoma.
Ye T, Zhang JY, Liu XY, Zhou YH, Yuan SY, Yang MM, Xie WZ, Gao C, Chen YX, Huang ML, Ye CZ, Chen J., Free PMC Article | 03/5/2022 |
| The copper chaperone CCS facilitates copper binding to MEK1/2 to promote kinase activation. | The copper chaperone CCS facilitates copper binding to MEK1/2 to promote kinase activation.
Grasso M, Bond GJ, Kim YJ, Boyd S, Matson Dzebo M, Valenzuela S, Tsang T, Schibrowsky NA, Alwan KB, Blackburn NJ, Burslem GM, Wittung-Stafshede P, Winkler DD, Marmorstein R, Brady DC., Free PMC Article | 01/29/2022 |
| Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells. | Dual Inhibition of DKC1 and MEK1/2 Synergistically Restrains the Growth of Colorectal Cancer Cells.
Kan G, Wang Z, Sheng C, Chen G, Yao C, Mao Y, Chen S., Free PMC Article | 01/8/2022 |
| Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020. | Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
Tang X, Gao J, Ma ZG, Guo X, Li Q, Wan Z, Sun JJ., Free PMC Article | 01/1/2022 |
| Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer. | Oncoprotein HBXIP promotes tumorigenesis through MAPK/ERK pathway activation in non-small cell lung cancer.
Zhang J, Sun B, Ruan X, Hou X, Zhi J, Meng X, Zheng X, Gao M., Free PMC Article | 12/18/2021 |
| MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway. | MAP2K1 Mutations in Advanced Colorectal Cancer Predict Poor Response to Anti-EGFR Therapy and to Vertical Targeting of MAPK Pathway.
Chuang J, Wang C, Guo Y, Valenzuela V, Wu J, Fakih M. | 12/18/2021 |
| Expanding spectrum of ""spitzoid"" lesions: a small series of 4 cases with MAP2K1 mutations. | Expanding spectrum of "spitzoid" lesions: a small series of 4 cases with MAP2K1 mutations.
Kerckhoffs KGP, Aallali T, Ambarus CA, Sigurdsson V, Jansen AML, Blokx WAM., Free PMC Article | 10/23/2021 |
| Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations. | Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.
Williams EA, Montesion M, Shah N, Sharaf R, Pavlick DC, Sokol ES, Alexander B, Venstrom J, Elvin JA, Ross JS, Williams KJ, Tse JY, Mochel MC., Free PMC Article | 10/16/2021 |
| IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas. | IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
Wang Q, Zhang Y, Zhu J, Zheng H, Chen S, Chen L, Yang HS., Free PMC Article | 10/9/2021 |
| Distribution and Functional Consequences of Somatic MAP2K1 Variants in Affected Skin Associated with Bone Lesions in Melorheostosis. | Distribution and Functional Consequences of Somatic MAP2K1 Variants in Affected Skin Associated with Bone Lesions in Melorheostosis.
Jha S, Ivovic A, Kang H, Meylan F, Hanson EP, Rimland C, Lange E, Katz J, McBride A, Warner AC, Edmondson EF, Cowen EW, Marini JC, Siegel RM, Bhattacharyya T., Free PMC Article | 10/9/2021 |
| Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells. | Quadruple-editing of the MAPK and PI3K pathways effectively blocks the progression of KRAS-mutated colorectal cancer cells.
Wang Z, Kang B, Gao Q, Huang L, Di J, Fan Y, Yu J, Jiang B, Gao F, Wang D, Sun H, Gu Y, Li J, Su X., Free PMC Article | 09/18/2021 |
| Molecular mechanisms underlying cellular effects of human MEK1 mutations. | Molecular mechanisms underlying cellular effects of human MEK1 mutations.
Marmion RA, Yang L, Goyal Y, Jindal GA, Wetzel JL, Singh M, Schüpbach T, Shvartsman SY., Free PMC Article | 09/18/2021 |
| MEK1/2 activity modulates TREM2 cell surface recruitment. | MEK1/2 activity modulates TREM2 cell surface recruitment.
Schapansky J, Grinberg YY, Osiecki DM, Freeman EA, Walker SG, Karran E, Gopalakrishnan SM, Talanian RV., Free PMC Article | 08/28/2021 |
| Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations. | Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations.
Scheffler M, Holzem A, Kron A, Nogova L, Ihle MA, von Levetzow C, Fassunke J, Wömpner C, Bitter E, Koleczko S, Abdulla DSY, Michels S, Fischer R, Riedel R, Weber JP, Westphal T, Gerigk U, Kern J, Kaminsky B, Randerath W, Kambartel KO, Merkelbach-Bruse S, Büttner R, Wolf J. | 08/28/2021 |
| Novel genetic alteration in congenital melanocytic nevus: MAP2K1 germline mutation with BRAF somatic mutation. | Novel genetic alteration in congenital melanocytic nevus: MAP2K1 germline mutation with BRAF somatic mutation.
Zou Y, Sun Y, Zeng X, Liu Y, Cen Q, Gu H, Lin X, Cai R, Chen H., Free PMC Article | 07/31/2021 |